BPC-157 dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of BPC-157 actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
BPC-157 reconstitution chart
Units on a standard U-100 insulin syringe, where 100 units is 1 mL. The rows are the absolute doses quoted in studies of BPC-157, from 10 mcg to 100 mg, so this chart is specific to this compound rather than a generic ladder. More diluent means more units for the same dose, which is easier to measure accurately and empties the vial no faster.
| Dose | 1 mL diluent (2,000 mcg/mL) | 2 mL diluent (1,000 mcg/mL) | 3 mL diluent (667 mcg/mL) |
|---|---|---|---|
| 10 mcg | 0.5 | 1 | 1.5 |
| 5 mg | 250 >1 mL | 500 >1 mL | 750 >1 mL |
| 20 mg | 1,000 >1 mL | 2,000 >1 mL | 3,000 >1 mL |
| 100 mg | 5,000 >1 mL | 10,000 >1 mL | 15,000 >1 mL |
| Dose | 1 mL diluent (5,000 mcg/mL) | 2 mL diluent (2,500 mcg/mL) | 3 mL diluent (1,667 mcg/mL) |
|---|---|---|---|
| 10 mcg | 0.2 | 0.4 | 0.6 |
| 5 mg | 100 | 200 >1 mL | 300 >1 mL |
| 20 mg | 400 >1 mL | 800 >1 mL | 1,200 >1 mL |
| 100 mg | 2,000 >1 mL | 4,000 >1 mL | 6,000 >1 mL |
| Dose | 1 mL diluent (10,000 mcg/mL) | 2 mL diluent (5,000 mcg/mL) | 3 mL diluent (3,333 mcg/mL) |
|---|---|---|---|
| 10 mcg | 0.1 | 0.2 | 0.3 |
| 5 mg | 50 | 100 | 150 >1 mL |
| 20 mg | 200 >1 mL | 400 >1 mL | 600 >1 mL |
| 100 mg | 1,000 >1 mL | 2,000 >1 mL | 3,000 >1 mL |
Read a figure off this chart only if it matches the vial in front of you. A vial labelled a different strength, or reconstituted with a different volume, gives a different number for the same dose, and that is the single most common way these calculations go wrong.
Doses in published studies of BPC-157
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. 1 of 6 come from human studies; the rest are animal or laboratory work.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Observational, human | Human study, humans, n=2, 2025: doses stated in the abstract: 20 mg. Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. | pmid-40131143 |
| Animal, preclinical | Animal study, rats, 2026: doses stated in the abstract: 10 µg/kg/day. Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500… | pmid-42542926 |
| Animal, preclinical | Animal study, rats, n=6, 2026: doses stated in the abstract: 20 µg/kg. BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups. | pmid-42204242 |
| Animal, preclinical | Animal study, rats, 2026: doses stated in the abstract: 10 ng/kg. BPC 157 (10 ng/kg intragatrically immediately after unilateral adrenalectomy) produced a clear, reproducible separation of aortic spectra from control samples at all time points. | pmid-41599787 |
| Animal, preclinical | Animal study, rats, 2026: doses stated in the abstract: 10 µg; 10 ng. Tracheocutaneous fistula rats received daily medication (/kg), alone or combined, BPC 157 therapy (10 µg, 10 ng, in drinking water or intraperitoneally) along with a triple NO-agent approach (L-NAME 5 mg, L-arginine 100 mg, and L-NAME+L-arginine, intraperitoneally). | pmid-41599743 |
| Animal, preclinical | Animal study, rats, 2025: doses stated in the abstract: 10 µg; 10 ng. Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both… | pmid-39861766 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- Animal study, rats, 2026: weight-normalized doses as published: 10 µg/kg/day. Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day),… pmid-42542926
- Animal study, rats, n=6, 2026: weight-normalized doses as published: 20 µg/kg. BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups. pmid-42204242
- Animal study, rats, 2026: weight-normalized doses as published: 10 ng/kg. BPC 157 (10 ng/kg intragatrically immediately after unilateral adrenalectomy) produced a clear, reproducible separation of aortic spectra from control samples at all time points. pmid-41599787
- Animal study, rats, 2023: weight-normalized doses as published: 10 µg/kg; 10 ng/kg. Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ… pmid-38004420
- Animal study, rats, 2023: weight-normalized doses as published: 10 µg/kg; 10 ng/kg. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically). pmid-37895979
- Animal study, rats, 2023: weight-normalized doses as published: 10 ng/kg. BPC 157 therapy (10 µg, 10 ng/kg given intragastrically at 5 min or 90 min sotalol-time) effectively counteracted sotalol-occlusion/occlusion-like syndrome. pmid-37513889
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of BPC-157 actually ran for.
- Human study, humans, n=2, 2025: durations stated: 58 year; 68 year. Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial. pmid-40131143
- Animal study, rats, 2025: durations stated: 3 months. Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and… pmid-39861766
- Animal study, rats, n=157, 2022: durations stated: 1 year; 4 days. Besides the demonstrated rapid and sustained recovery (1 year), we showed the particular points of the immediate effect of the BPC 157 therapy that began rapidly after its administration, (i) soon after injury (10 min), or (ii) later (4 days), in the rats with a… pmid-35678659
- Animal study, rats, 2021: durations stated: 28 days; 42 days. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. pmid-34829776
Storage and stability, as published
Reconstitution starts a clock. These are the storage and stability conditions stated in papers in this ledger. They describe what the study did, which is not the same as a shelf life for a vial in your fridge.
- In vitro study, humans, 2022: In this paper, we summarize the evidence of the native cytoprotective gastric pentadecapeptide BPC 157, which is stable in the human gastric juice, is a membrane stabilizer and counteracts gut-leaky syndrome. pmid-35125818
How BPC-157 was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Human study, humans, n=2, 2025: administration by intravenous route reported. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. pmid-40131143
- Human study, humans, 2021: administration by oral route reported. Those results were complemented by strong and visible LAP activity, particularly noticeable in the apical parts of the epithelial cells in the mid-guts of young worker honeybees originated from treated hives, suggesting a link between alternative oral therapy with BPC 157… pmid-34571768
- Animal study, rats, n=6, 2026: administration by intraperitoneal route reported. BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups. pmid-42204242
- Animal study, rats, 2026: administration by intraperitoneal route reported. Tracheocutaneous fistula rats received daily medication (/kg), alone or combined, BPC 157 therapy (10 µg, 10 ng, in drinking water or intraperitoneally) along with a triple NO-agent approach (L-NAME 5 mg, L-arginine 100 mg, and L-NAME+L-arginine,… pmid-41599743
- Animal study, rats, 2025: administration by oral route reported. This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration. pmid-39861766
- Animal study, rats, 2023: administration by subcutaneous route reported. Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ lesions and… pmid-38004420
Questions people ask
- How many units is 10 mcg of BPC-157?
- It depends entirely on how the vial was reconstituted. In a 5 mg vial with 2 mL of diluent it is 0.4 units on a U-100 syringe; with 1 mL it is 0.2. The chart above gives the rest.
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the BPC-157 record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. A dose that appeared in a trial appeared under supervision, with monitoring, in people selected for that trial.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures